Table 3 Total cohort split according to 3 clusters
From: The epidemiology of primary FSGS including cluster analysis over a 20-year period
Variable | Cluster 1 (n= 26) | Cluster 2 (n= 43) | Cluster 3 (n= 18) | P-value | |
|---|---|---|---|---|---|
Age | 47.0 (+/- 15.4) | 43.5 (+/- 12.1) | 60.5 (+/- 16.4) | 0.004 | |
Male | 15 (57.7) | 28 (65.1) | 10 (55.6) | 0.723 | |
White ethnicity | 20 (76.9) | 39 (90.7) | 16 (88.9) | 0.256 | |
Diabetes | 3 (12) | 5 (11.6) | 0 (0) | 0.311 | |
Hypertension | 12 (48) | 26 (60.5) | 8 (44.4) | 0.420 | |
Cardiovascular disease | 3 (11.5) | 8 (18.6) | 2 (11.1) | 0.638 | |
Systolic BP at biopsy, mmHg | 122 (116.8 – 130) | 130 (120 – 142.3) | 132 (120-140) | 0.018 | |
Diastolic BP at biopsy, mmHg | 75.7 (+/- 9.5) | 81.2 (+/-12.0) | 78.1 (+/-12.1) | 0.005 | |
Creatinine, µmol/L | 93.5 (63.3 – 110.5) | 139.5 (119.3 – 222) | 226 (166 – 272) | <0.001 | |
eGFR, ml/min/1.73m2 | 80 (52 – 90) | 38.5 (27.3 – 58) | 22 (16 – 39) | <0.001 | |
uPCR, mg/mmol | 782 (617 – 930.3) | 227 (173.3 – 373) | 852 (776 – 1456) | <0.001 | |
Haemoglobin, g/L | 122 (105.5 – 134) | 127 (108.8 – 157.8) | 113 (106 – 120) | 0.002 | |
Corrected calcium, mmol/L | 2.31 (2.23 – 2.43) | 2.37 (2.28 – 2.45) | 2.31 (2.23 – 2.36) | 0.664 | |
Phosphate, mmol/L | 1.25 (1.15 – 1.35) | 1.14 (0.98 – 1.33) | 1.35 (1.24 – 1.74) | 0.01 | |
Albumin at biopsy, g/L | 29 (24.3 – 34.5) | 42 (37.3 – 43.8) | 20 (17- 22) | <0.001 | |
Immunosuppression | 18 (69.2) | 5 (11.6) | 14 (77.8) | <0.001 | |
Albumin at TOI, g/L | 27 (21 -33) | 30 (26.5 – 40.5) | 18 (17 – 23.5) | 0.003 | |
Presented with nephrotic syndrome | 12 (41.4) | 0 (0) | 17 (94.4) | <0.001 | |
Remission | Partial | 6 (23.1) | 11 (25.6) | 3 (16.7) | 0.752 |
Complete | 15 (57.7) | 16 (37.2) | 12 (66.7) | 0.067 | |
Combined | 21 (80.8) | 27 (62.8) | 15 (83.3) | 0.137 | |
Time to remission, days | 288.5 (147 – 734.5) | 807 (196.5 – 1880) | 195 (76 – 612) | 0.006 | |
Relapse | 13 (50.0) | 9 (21.4) | 7 (38.9) | 0.046 | |
ACEi/ ARB | 22 (84.6) | 36 (83.7) | 9 (50) | 0.009 | |
RRTa | Total | 5 (19.2) | 13 (30.2) | 6 (33.3) | 0.507 |
5 year | 3 (11.5) | 6 (14) | 6 (33.3) | 0.123 | |
10 year | 4 (15.4) | 12 (27.9) | 6 (33.3) | 0.346 | |
Mortalitya | Total | 3 (11.5) | 13 (30.2) | 8 (44.4) | 0.048 |
5 year | 2 (7.7) | 3 (7.0) | 4 (22.2) | 0.177 | |
10 year | 2 (7.7) | 10 (23.3) | 5 (27.8) | 0.176 | |
Follow up duration, months | 111 (54.5 – 147.5) | 112 (47.3 – 142) | 86 (19 – 129) | 0.532 | |